Demonstration of Menon Lab-in-the-Box system for aquaculture in India
Menon Lab-in-the-Box system and assays are demonstrated and routinely used for microbial monitoring of shrimp hatcheries and farms in India.
SAN DIEGO, June 1, 2015 – Over the last couple of years, Menon Biosensors, Inc. (MBI) has demonstrated its Lab-in-the-Box pathogen detector using its M2 (Molecular Mirroring) nuclear magnetic resonance (NMR) and nanoparticle technology in India. Several reputable aquaculture companies that own hatcheries and ponds throughout India have been operating Menon’s Lab-in-the-Box system and proprietary assays for microbial monitoring.
Several challenges faced by the aquaculture industry today have been solved using Menon’s system and assays in India. After successful tests, the hatcheries are confident that the Lab-in-the-Box system and assays developed by MBI provide the ideal solution to rapidly detect different bacteria, virus, fungi and parasites seen in aquaculture facilities. One of the most lethal diseases affecting shrimp today is “Early Mortality Syndrome” (EMS) or “Acute Hepatopancreatic Necrosis Disease” (AHPND). EMS/AHPND is currently spreading worldwide, causing substantial economic losses for shrimp farms. MBI has developed a highly specific, quantitative assay for detection of the particular variant of Vibrio parahaemolyticus which has been identified as the causative agent of EMS/AHPND.
Several additional assays have been developed and demonstrated for hatcheries and ponds, including detection of general Vibrio species, White Spot Syndrome Virus (WSSV), and other general bacteria species seen in shrimp farms and hatcheries. In addition to detecting specific pathogens affecting aquaculture species, microbial management strategies are employed by clients in India with the help of the Menon team. These strategies can prevent the risk of EMS/AHPND and other disease outbreaks by continuous monitoring of various microbial populations.
“This technology has a wide range of applications in aquaculture by rapidly detecting disease causing bacteria, viruses, fungi and parasites while delivering unmatched sensitivity, lowest-cost, and fastest detection of nucleic acids compared to most of the nucleic acid methods available today” stated Dr. Suresh Menon, Ph.D., President of Menon Biosensors, Inc. Continued Dr. Menon. “We intend to expand marketing and sales of M2 technology for aquaculture in India in the coming years.”
About Menon Biosensors’ Platform Technology
M2 technology was developed initially to establish rapid countermeasures against bioterrorism. Menon’s technology provides superior results that enable officials to make intelligent, quick decisions following detection and exposure to lethal bacterial agents such as Anthrax (Bacillus anthracis) and Plague (Yersinia pestis). Testing of Menon’s biosensor technology to detect against bioterrorist attack became public information in a press release by the Department of Homeland Security in August 2012.
Menon Biosensors’ M2 technology has been validated through multiple studies with the U.S. government’s Biodefense Programs. In these studies, conducted with more than 3,000 samples over a six-year period, the technology demonstrated greater than 99 percent accuracy in the presence of interferants and near neighbors of the pathogens to be detected.
About Menon Biosensors, Inc.
Menon Biosensors is a molecular biochemistry company that provides DNA analysis for the diagnosis of biological pathogens. Menon Biosensors’ microfluidics and M2 NMR platform technology (classified by the U.S. Government until 2012) provides superior sensitivity and specificity and minimizes sample preparation, providing best in class sample-to-answer pathogen detection. The technology has been validated by respected third parties in more than 3,000 samples over six years.
858-675-9990 Ext 113